Multiple Sclerosis (Relapsing Remitting) Clinical Trial
Official title:
A 12 Month Study, With a 6-month, Double-blind, Randomized, Placebo-controlled, Multi-center Parallel- Groups, Treatment Phase Evaluating Efficacy and Safety of Fingolimod 0.5 mg and a 6-month, Open-label, Treatment Phase, in Chinese Patients With Relapsing-remitting Multiple Sclerosis
To evaluate the safety and efficacy of fingolimod 0.5mg vs. placebo in MS patients in China
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01518660 -
Multiple Sclerosis and Progressive Resistance Training
|
N/A |